{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"31","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Progression-free survival rate is the percentage of patients who do not show signs of progression at 2 years after registration to the study, including those whose disease has either completely or partially responded to treatment, or those whose disease is stable. Progression-free survival is defined as the time between study registration and documented progression, or death if no progression was observed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received IV cisplatin 25 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4, gemcitabine 1000 mg/m2 day 1 and solumedrol 250 mg days 1-4 of a 21 day cycle for 6 cycles.","id":"OG000","title":"PEGS"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started protocol treatment were included in the analysis.","timeFrame":"0-2 years","title":"2-year Progression-free Survival Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}